Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 3/20 | 0.46 |
| ▸ | MT-CO2 | P00403 | 2/20 | 0.37 |
| ▸ | GLA | P06280 | 2/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.35 |
| ▸ | ESR1 | P03372 | 1/20 | 0.35 |
| ▸ | PGR | P06401 | 1/20 | 0.35 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.35 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.35 |
| ▸ | AR | P10275 | 1/20 | 0.35 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.35 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.35 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.34 |
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
| ▸ | LMNA | P02545 | 1/20 | 0.34 |
| ▸ | GAA | P10253 | 1/20 | 0.34 |
| ▸ | CASP1 | P29466 | 1/20 | 0.34 |
| ▸ | CASP7 | P55210 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6639439 | 0.88 | GLA (0.38) | MAPTGLAALDH1A1ESR1PGR | |
| SCHEMBL3943458 | 0.82 | MAPT (0.49) | MAPTMT-CO2ALDH1A1KDM4EMEN1 | |
| SCHEMBL21612449 | 0.81 | MAPT (0.40) | MAPTMT-CO2ALDH1A1MEN1LMNA | |
| SCHEMBL11902792 | 0.79 | MAPT (0.43) | MAPTMT-CO2MEN1KMT2A | |
| SCHEMBL14637386 | 0.79 | MAPT (0.43) | MAPTMT-CO2KDM4E | |
| SCHEMBL9397681 | 0.79 | — | — | |
| Bicarbonate SCHEMBL9807679 | 0.78 | MAPT (0.51) | MAPTMT-CO2ALDH1A1 | |
| SCHEMBL3940279 | 0.77 | MAPT (0.48) | MAPTMT-CO2ALDH1A1SLC6A2SLC6A3 | |
| SCHEMBL125003 | 0.76 | — | — | |
| SCHEMBL9298583 | 0.76 | KMT2A (0.43) | MAPTMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240067621-A1 | POLYFLUORINATED CANNABINOID AND CANNABINOID-LIKE COMPOUNDS AND METHODS OF SYNTHESIS AND USE THEREOF | WEAVER JIMMIE D (US) | 2024-02-29 | — | — | US | disclosed |
| EP-4298096-A1 | POLYFLUORINATED DICYCLIC COMPOUNDS AND METHODS OF SYNTHESIS THEREOF | The Board of Regents for the Oklahoma Agricultural And Mechanical Colleges (US) | 2024-01-03 | — | — | EP | disclosed |
| WO-2022182623-A1 | POLYFLUORINATED DICYCLIC COMPOUNDS AND METHODS OF SYNTHESIS THEREOF | BOARD OF REGENTS FOR OKLAHOMA AGRICULTURAL AND MECHANICAL COLLEGES (US) | 2022-09-01 | — | — | WO | disclosed |
| US-8697744-B2 | Substituted 5,6-dihydro-4H-thiazolo[4,5-E]indazoles and their use as positive allosteric modulators of metabotropic glutamate receptors | ADDEX PHARMA S.A. (CH) | 2014-04-15 | — | — | US | disclosed |
| US-20110319425-A1 | HETEROTRICYCLIC COMPOUNDS AS POSITIVE ALLOSTERIC MODULATORS OF METABOTROPIC GLUTAMATE RECEPTORS | ADDEX PHARMA SA (CH) | 2011-12-29 | — | — | US | disclosed |
| EP-2382219-A1 | HETEROTRICYCLIC COMPOUNDS AS POSITIVE ALLOSTERIC MODULATORS OF METABOTROPIC GLUTAMATE RECEPTORS | ADDEX Pharma S.A. (CH) | 2011-11-02 | — | — | EP | disclosed |
| WO-2010079238-A1 | HETEROTRICYCLIC COMPOUNDS AS POSITIVE ALLOSTERIC MODULATORS OF METABOTROPIC GLUTAMATE RECEPTORS | ADDEX PHARMA S.A. (CH) | 2010-07-15 | — | — | WO | disclosed |
| US-7501544-B2 | Process for the production of cyclic diketones | SYNGENTA CROP PROTECTION, INC. (US) | 2009-03-10 | — | — | US | disclosed |
| US-20070232837-A1 | Process for the Production of Cyclic Diketones | SYNGENTA CROP PROTECTION, INC. (US) | 2007-10-04 | — | — | US | disclosed |
| EP-1529092-B1 | GAS ODORISATION USING KETONES | SYMRISE GMBH & CO KG (DE) | 2007-07-04 | — | — | EP | disclosed |
| EP-1483442-A2 | NOVEL CATALYTIC ACTIVITIES OF OXIDOREDUCTASES FOR OXIDATION AND/OR BLEACHING | Call, Krimhild (DE) | 2004-12-08 | — | — | EP | disclosed |
| EP-1436371-A2 | ENZYMATIC SYSTEMS FOR GENERATING ACTIVE OXYGEN SPECIES FOR REACTING WITH OTHER PRECURSORS TO OBTAIN OXIDATION AND/OR BLEACHING | Call, Krimhild (DE) | 2004-07-14 | — | — | EP | disclosed |
| WO-2003061550-A2 | NOVEL CATALYTIC ACTIVITIES OF OXIDOREDUCTASES FOR OXIDATION AND/OR BLEACHING | CALL, KRIMHILD (DE) | 2003-07-31 | — | — | WO | disclosed |
| EP-1324993-A2 | SUBSTITUTED 1,4-THIAZEPINE AND ANALOGS AS ACTIVATORS OF CASPASES AND INDUCERS OF APOPTOSIS AND THE USE THEREOF | Cytovia, Inc. (US) | 2003-07-09 | — | — | EP | disclosed |
| WO-2002099023-A2 | ENZYMATIC SYSTEMS FOR GENERATING ACTIVE OXYGEN SPECIES FOR REACTING WITH OTHER PRECURSORS TO OBTAIN OXIDATION AND/OR BLEACHING | CALL, KRIMHILD (DE) | 2002-12-12 | — | — | WO | disclosed |
| US-20020010169-A1 | Substituted 1, 4-thiazepine and analogs as activators of caspases and inducers of apoptosis and the use thereof | CYTOVIA, INC. | 2002-01-24 | — | — | US | disclosed |
| WO-2001079187-A2 | SUBSTITUTED 1,4-THIAZEPINE AND ANALOGS AND THEIR USE AS ACTIVATORS OF CASPASES | CYTOVIA, INC. (US) | 2001-10-25 | — | — | WO | disclosed |
| EP-1012376-A2 | OXIDATION AND BLEACHING SYSTEM WITH ENZYMATICALLY PRODUCED OXIDIZING AGENTS | Blume, Hildegard (DE) | 2000-06-28 | — | — | EP | disclosed |
| WO-1998059108-A2 | OXIDATION AND BLEACHING SYSTEM WITH ENZYMATICALLY PRODUCED OXIDIZING AGENTS | BLUME, HILDEGARD (DE) | 1998-12-30 | — | — | WO | disclosed |
| EP-0331422-A2 | Method of preparing 2-acylresorcinols | MITSUI PETROCHEMICAL INDUSTRIES, LTD. (JP) | 1989-09-06 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240067621-A1 | POLYFLUORINATED CANNABINOID AND CANNABINOID-LIKE COMPOUNDS AND METHODS OF SYNTHESIS AND USE THEREOF | CNR2, CNR1, FAAH | MAPT 2088/4885MT-CO2 2327/4885GLA 1458/4885 |
| US-20070232837-A1 | Process for the Production of Cyclic Diketones | CA9, ACAD9, F9 | MAPT 4489/4885MT-CO2 191/4885GLA 2112/4885 |
| US-20110319425-A1 | HETEROTRICYCLIC COMPOUNDS AS POSITIVE ALLOSTERIC MODULATORS OF METABOTROPIC GLUTAMATE RECEPTORS | GRM1, GRM4, GRM2 | MAPT 1997/4885MT-CO2 2082/4885GLA 4040/4885 |
| US-20020010169-A1 | Substituted 1, 4-thiazepine and analogs as activators of caspases and inducers of apoptosis and the use thereof | CASP1, CASP14, CASP4 | MAPT 3104/4885MT-CO2 2799/4885GLA 996/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.